The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
  • Tech
  • Bio
  • Companies
Thu, August 18, 2022 | 07:52
Companies
Samsung, SK in race to gain lead in CDMO market
Posted : 2022-05-10 19:02
Updated : 2022-05-11 14:25
Print Preview
Font Size Up
Font Size Down
Samsung Biologics' third CDMO production facility in Songdo, Incheon / Courtesy of Samsung Biologics
Samsung Biologics' third CDMO production facility in Songdo, Incheon / Courtesy of Samsung Biologics

By Kim Jae-heun

Samsung Biologics and SK Bioscience plan to invest heavily in the contract development and manufacturing organization (CDMO) market, which the two firms believe will be their next growth engine.

CDMO, which combines a contract manufacturing organization (CMO) and contract development organization (CDO), refers to the development and production of medicine at the request of a client company that lacks any medical production facilities.

Samsung and SK already demonstrated their global competitiveness last year by achieving record-high business performance after inking major COVID-19 vaccine production deals.

This year, the two companies are planning even more aggressive investments in the CDMO field.

Samsung Biologics is preparing to open its fourth factory in Songdo, Incheon, which will be the world's largest bio production facility. SK Bioscience will strengthen its competitiveness in the CDMO market by establishing a research and development center in Songdo in 2024.

Bio firms have been expanding their CDMO capacity, because the global market size is growing at a fast rate and it has become essential to strengthen their production capabilities.

According to a study by the Korea Biotechnology Industry Organization released on May 1, the size of the global CDMO market will reach $20.3 billion (25.1 trillion won) by 2026 from $11.3 billion in 2020.

As of 2020, there were more than 100 CDMO companies and the top five companies -- Lonza, Samsung Biologics, Catalent, Boehringer Ingelheim and Thermo Fisher -- account for 59.4 percent of the total market.

Samsung Biologics is the No.1 player in the domestic CDMO market. Last year, it achieved 1.56 trillion won in sales and 537.3 billion won in operating profit, which were record-high numbers owing to the production of COVID-19 vaccines developed by Moderna.

Samsung built its first CDMO factory in Songdo in 2011 and currently runs three. A new fourth production facility will manufacture 256,000 liters of medicine annually, which is the largest output capacity in the world for a single plant.

"We will begin construction of a fifth plant by the end of this year. We will be focusing on expanding our production capacity by establishing a mass production facility for antibody drugs and an Open Innovation Center in Songdo," a Samsung Biologics official said.

SK Bioscience had a successful year with sales reaching nearly 1 trillion won in 2021. It won a CMO contract to produce COVID-19 vaccines developed by AstraZeneca and a CDMO contract to make COVID-19 vaccines developed by Novavax in 2021.

"We will actively sign corporate acquisition deals to enter new biotech fields such as CGT and secure technologies such as mRNA vaccines in the next three to four years. Here, we will invest some 5 trillion won to 6 trillion won," a SK Bioscience official said.


Emailjhkim@koreatimes.co.kr Article ListMore articles by this reporter
 
LG
  • Samsung's defective washing machine fans consumer concerns
  • [INTERVIEW] Moon rallies int'l support for unification of two Koreas
  • Standard Chartered Bank chief to visit Seoul in late August
  • Yoon confident about Korea hosting World Expo 2030
  • 'Labor law should be changed in line with Fourth Industrial Revolution'
  • Envoy raises awareness of Korea among Serbian public
  • [INTERVIEW] Data essential for 'evidence-based decisions': Statistics Korea commissioner
  • Yoon opposes forceful change to status quo in North Korea
  • Korea urged to overhaul pension, tax systems to cope with rapidly-aging population
  • What polls don't say about Yoon
  • Interactive News
  • With tough love,
  • 'Santa dogs' help rebuild burnt forests in Andong
  • 'Santa dogs' help rebuild burnt forests in Andong
  • A tale of natural wine
    • 2PM's Lee Jun-ho proves versatility at 'Before Midnight' concert 2PM's Lee Jun-ho proves versatility at 'Before Midnight' concert
    • 'Confidential Assignment 2' has even more action, humor 'Confidential Assignment 2' has even more action, humor
    • [INTERVIEW] Director of 'A Model Family' on blending Korean and European-style thrillers [INTERVIEW] Director of 'A Model Family' on blending Korean and European-style thrillers
    • Thriller series 'Flower Of Evil' becomes first K-drama to be remade in India Thriller series 'Flower Of Evil' becomes first K-drama to be remade in India
    • 'Extraordinary Attorney Woo' to be made into musicals in 2024 'Extraordinary Attorney Woo' to be made into musicals in 2024
    DARKROOM
    • Ice is melting, land is burning

      Ice is melting, land is burning

    • Tottenham 6-3 Team K League

      Tottenham 6-3 Team K League

    • Afghanistan earthquake killed more than 1,000

      Afghanistan earthquake killed more than 1,000

    • Divided America reacts to overturn of Roe vs. Wade

      Divided America reacts to overturn of Roe vs. Wade

    • Namaste: Yogis to celebrate International Yoga Day

      Namaste: Yogis to celebrate International Yoga Day

    The Korea Times
    CEO & Publisher : Oh Young-jin
    Digital News Email : webmaster@koreatimes.co.kr
    Tel : 02-724-2114
    Online newspaper registration No : 서울,아52844
    Date of registration : 2020.02.05
    Masthead : The Korea Times
    Copyright © koreatimes.co.kr. All rights reserved.
    • About Us
    • Introduction
    • History
    • Location
    • Media Kit
    • Contact Us
    • Products & Service
    • Subscribe
    • E-paper
    • Mobile Service
    • RSS Service
    • Content Sales
    • Policy
    • Privacy Statement
    • Terms of Service
    • 고충처리인
    • Youth Protection Policy
    • Code of Ethics
    • Copyright Policy
    • Family Site
    • Hankook Ilbo
    • Dongwha Group